

# CorNotes

## CVI SEMINAR SERIES

The next CVI Seminar will be held on **Thursday, February 21, 2008 at 4:00 pm** in **The Van Kampen Conference Center, Building 110, Room 6294**. Our speaker is:

**W. Robert Taylor, Ph.D., M.D.**  
**Professor of Medicine and Biomedical Engineering**  
**Emory University School of Medicine**  
**Atlanta, GA**

The title Dr. Taylor's talk will be announced at a subsequent mailing.

For further information about the CVI Seminar Series, contact Dr. Leanne Cribbs at x72817.

## CVI JOURNAL CLUB

February 14.....Dr. J. Walenga  
 February 28.....Dr. D. Hoppensteadt

CVI Journal Club is held at 12:00 noon in the CVI Research Division Conference Room, Rm 5215. For further information, contact Dr. Ken Byron at x72819.

## CARDIOLOGY – CVI RESEARCH DIVISION BASIC SCIENCE SEMINAR

The Cardiology Division and the CVI Research Division are sponsoring a series of joint seminars by Loyola Faculty. The following seminar is scheduled at **7:30 am** in the **Van Kampen Conference Center**:

February 14.....Dr. Kyle Henderson

The title of Dr. Henderson's talk is:

**"A Treatment For Cardiovascular Disease:  
 The "Drug" Is In Your Legs"**

For further information about the seminar series, contact Dr. Samarel at X72821.

## RECENT PUBLICATIONS FROM THE CVI

Joyal D, Leya F, Koh M, Besinger R, Ramana R, Kahn S, Jeske W, Lewis B, Steen L, Mestrlil R, Arab D. Troponin I levels in patients with preeclampsia. *Am J Med.* 120(9):819.e13-e14, 2007.

Colston JT, de la Rosa SD, Koehler M, Gonzales K, Mestrlil R, Freeman GL, Bailey SR, Chandrasekar B. Wnt-induced secreted protein-1 is a prohypertrophic and profibrotic growth factor. *Am J Physiol Heart Circ Physiol.* 293(3):H1839-1846, 2007.

Kumar P, Ambasta RK, Veereshwarayya V, Rosen KM, Kosik KS, Band H, Mestrlil R, Patterson C, Querfurth HW. CHIP and HSPs interact with beta-APP in a proteasome-dependent manner and influence Abeta metabolism. *Hum Mol Genet.* 16(7):848-864, 2007.

Walenga JM. Non-anticoagulant effects of unfractionated and low-molecular weight heparins. *Clin Adv Hematol Oncol.* 5(10):759-60, 2007.

Fareed J, Walenga JM. Why differentiate low molecular weight heparins for venous thromboembolism? *Thromb J.* 19:8, 2007.

Samarel AM and Walsh RA. Molecular and cellular biology of the normal, hypertrophied and failing heart. In *Hurst's the Heart, 12<sup>th</sup> Edition* (Fuster V, Alexander RW, O'Rourke RA, et al., eds.) McGraw-Hill, New York, January, 2008.

Fernandez A, Sanuino A, Peng Z, Ozturk E, Chen J, Crespo A, Wulf S, Shavrin A, Qin C, Ma J, Trent J, Lin Y, Han H-D, Mangala LS, Bankson JA, Gelovani J, Samarel AM, Bornmann W, Sood AK, Lopez-Berestein G. An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. *J. Clin. Invest.* 117:4044-4054, 2007

Demir M, Duran E, Yigitbasi O, Vural O, Kurum T, Yuksel M, Turgut B, Walenga JM, Fareed J. Incidence of antiheparin-platelet factor 4 antibodies and heparin-induced thrombocytopenia in Turkish patients undergoing cardiac surgery. *Clin Appl Thromb Hemost.* 13(3):279-84, 2007.

## NEW FALK FELLOWSHIP AWARDED

A 2-year Falk Cardiovascular Research Fellowship has been awarded to **Yevgeniya Koshman, Ph.D.** Dr. Koshman received the Ph.D. degree in Bioengineering from the University of Illinois – Chicago under the direction of Dr. Brenda Russell. She then joined the CVI Research Division in December, 2007 as a Research Associate in Medicine in the laboratory of Dr. Allen Samarel. Dr. Koshman's research project deals with mechanotransduction in vascular smooth muscle and endothelial cells.



Of note, Dr. Koshman is the 17<sup>th</sup> postdoctoral fellow to receive a Falk Cardiovascular Research Fellowship since inception of the program in 1996.

## ASCEND-HF TRIAL

Dr. Alain Heroux of the section of Heart Failure/Transplant is the principal investigator conducting the ASCEND-HF clinical trial on behalf of Scios. This is a double-blind, placebo-controlled, multicenter acute study of clinical effectiveness of nesiritide in subjects with decompensated heart failure.

This trial's purpose is to evaluate whether treatment with nesiritide improves patient outcomes (as measured by reduction in the composite of HF rehospitalization and all-cause mortality through 30 days after randomization) or HF symptoms (as measured by subject self-assessed Likert dyspnea scale at 6 hours and 24 hours after study drug initiation) compared with placebo, when each is administered in addition to other standard therapies in patients with acute decompensated heart failure.

This study is the largest clinical study in the field of acute decompensated heart failure and will provide extensive data to allow conclusive assessment of benefits and risks of nesiritide compared with currently available therapies.

For more information or to alert the Heart Failure/Transplant team of potential participants, please contact the project's coordinator, Cindy Finn, at 708-216-2646.

## WHITE MEMORIAL FUND

Just another reminder that an endowment fund has been established to defray the cost of student travel and presentation at scientific meetings, and to support the cost of publishing scientific manuscripts by medical and graduate students. The endowment has been funded by Richard E. White and Angeline (Faye) Schrater in memory of Mr. White's parents. Faculty members who require travel support for their students to attend scientific meetings, or to defray publication costs of student papers, should direct written requests for funding to Dr. Samarel, Director of Research, CVI.